The Sensory Disorders drugs in development market research report provides comprehensive information on the therapeutics under development for Sensory Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Sensory Disorders. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Sensory Disorders and features dormant and discontinued products.
GlobalData tracks 18 drugs in development for Sensory Disorders by 18 companies/universities/institutes. The top development phase for Sensory Disorders is preclinical with ten drugs in that stage. The Sensory Disorders pipeline has 12 drugs in development by companies and six by universities/ institutes. Some of the companies in the Sensory Disorders pipeline products market are: Johns Hopkins University, SATT Conectus Alsace and Fujian Normal University.
The key targets in the Sensory Disorders pipeline products market include Tryptophan 5 Hydroxylase 1 (Tryptophan 5 Monooxygenase 1 or TPH1 or EC 1.14.16.4), Transforming Growth Factor Beta 1 (TGFB1), and Mu Type Opioid Receptor (MOR1 or Mu Opiate Receptor or Mu Opioid Receptor or OPRM1).
The key mechanisms of action in the Sensory Disorders pipeline product include Mu Type Opioid Receptor (MOR1 or Mu Opiate Receptor or Mu Opioid Receptor or OPRM1) Agonist with one drug in Preclinical. The Sensory Disorders pipeline products include four routes of administration with the top ROA being Oral and eight key molecule types in the Sensory Disorders pipeline products market including Small Molecule, and Synthetic Peptide.
Sensory Disorders overview
Sensory Disorders or sensory processing disorders (SPD) is a neurological condition in children that affects the sensory stimuli of brain. It is also known as sensory integration dysfunction causing an increased or decreased sensitivity to light, smell, taste, sound, and touch. It is divided into 8 different types: proprioception, vestibular, interoception, and five senses. Hyposensitivity and hypersensitivity are observed in children. As a result, children shows behavioral problems, attention deficient, low pain threshold, difficulty in controlling emotions etc. ASD, Schizophrenia, brain injury, sleep disorders, developmental disorders are common conditions associated with this. There is no standard therapy for this condition hence cognitive supportive therapy provided.
For a complete picture of Sensory Disorders’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
